TScan Therapeutics (NASDAQ:TCRX) Given Overweight Rating at Morgan Stanley

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “overweight” rating restated by Morgan Stanley in a research note issued on Friday,Benzinga reports. They currently have a $10.00 price target on the stock. Morgan Stanley’s price target would indicate a potential upside of 474.71% from the stock’s previous close.

Other analysts have also recently issued research reports about the company. Barclays reduced their price target on TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Needham & Company LLC reduced their price target on TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, March 5th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a research report on Thursday, March 6th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $7.00 price target on shares of TScan Therapeutics in a research report on Wednesday, March 5th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $9.33.

TScan Therapeutics Price Performance

TCRX opened at $1.74 on Friday. The stock has a market cap of $92.87 million, a price-to-earnings ratio of -1.64 and a beta of 0.91. TScan Therapeutics has a 1 year low of $1.71 and a 1 year high of $9.69. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. The stock has a fifty day moving average price of $2.28 and a 200 day moving average price of $3.87.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02). The firm had revenue of $0.67 million for the quarter, compared to analyst estimates of $1.43 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. Analysts forecast that TScan Therapeutics will post -1.12 EPS for the current fiscal year.

Hedge Funds Weigh In On TScan Therapeutics

Institutional investors have recently made changes to their positions in the business. State Street Corp increased its stake in TScan Therapeutics by 24.4% during the third quarter. State Street Corp now owns 756,499 shares of the company’s stock valued at $3,767,000 after acquiring an additional 148,414 shares during the period. abrdn plc increased its stake in TScan Therapeutics by 137.8% during the fourth quarter. abrdn plc now owns 883,704 shares of the company’s stock valued at $2,686,000 after acquiring an additional 512,049 shares during the period. Geode Capital Management LLC increased its stake in TScan Therapeutics by 8.1% during the third quarter. Geode Capital Management LLC now owns 973,466 shares of the company’s stock valued at $4,849,000 after acquiring an additional 72,967 shares during the period. Stifel Financial Corp increased its stake in TScan Therapeutics by 3.9% during the third quarter. Stifel Financial Corp now owns 99,133 shares of the company’s stock valued at $494,000 after acquiring an additional 3,733 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of TScan Therapeutics in the 3rd quarter valued at approximately $112,000. 82.83% of the stock is currently owned by institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.